Retinal Degeneration - Pipeline Insight, 2018
This report can be delivered to the clients within 48 hours
'Retinal Degeneration- Pipeline Insight, 2018' report by DelveInsight outlays comprehensive Insight of present scenario and growth prospects across Retinal Degeneration. A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type. This report provides detailed analysis of 150+ products along with 120+ companies involved.
Products covered by Phase
Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.
Therapeutic segmentation of products for Retinal Degeneration
The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this indication.
METHODOLOGY
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
SCOPE OF THE REPORT
'Retinal Degeneration- Pipeline Insight, 2018' report by DelveInsight outlays comprehensive Insight of present scenario and growth prospects across Retinal Degeneration. A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type. This report provides detailed analysis of 150+ products along with 120+ companies involved.
Products covered by Phase
- Phase III, Phase II and Phase I
- Pre-clinical and Discovery
- Inactive (Dormant and Discontinued)
Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.
Therapeutic segmentation of products for Retinal Degeneration
The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this indication.
METHODOLOGY
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
SCOPE OF THE REPORT
- Provides an overview of therapeutic pipeline activity for Retinal Degeneration across the complete product development cycle including all clinical and non-clinical stages
- It comprises of detailed profiles of Retinal Degeneration therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
- Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
- Coverage of dormant and discontinued pipeline projects across Retinal Degeneration
- Establish a comprehensive understanding of the current pipeline scenario across Retinal Degeneration to formulate effective R&D strategies
- Assess challenges and opportunities that influence Retinal Degeneration R&D
- Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
- Identify the relationship between the products and use it for target finding, drug repurposing, and precision medicine
- Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Retinal Degeneration to enhance and expand business potential and scope
- Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs
- Provides an overview of therapeutic pipeline activity for Retinal Degeneration across the complete product development cycle including all clinical and non-clinical stages
- It comprises of detailed profiles of Retinal Degeneration therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
- Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
- Coverage of dormant and discontinued pipeline projects across Retinal Degeneration
Overview: Retinal Degeneration
Age-Related Macular Degeneration
Symptoms & Diagnosis
Treatment Options
Retinitis Pigmentosa
Symptoms & Diagnosis
Treatment
Stargardt Disease
Symptoms & Diagnosis
Treatment
Pipeline Therapeutics (Clinical Stage Products)
Comparative Analysis
Late Stage Products (Phase III)
Comparative Analysis
Abicipar: Allergan
Product Description
Research and Development
Product Development Activities
(The list continues)
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I)
Comparative Analysis
Pre-clinical & Discovery Stage Products
Comparative Analysis
Therapeutic Assessment: Active Products
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Inactive Products
Comparative Analysis
Appendix
Age-Related Macular Degeneration
Symptoms & Diagnosis
Treatment Options
Retinitis Pigmentosa
Symptoms & Diagnosis
Treatment
Stargardt Disease
Symptoms & Diagnosis
Treatment
Pipeline Therapeutics (Clinical Stage Products)
Comparative Analysis
Late Stage Products (Phase III)
Comparative Analysis
Abicipar: Allergan
Product Description
Research and Development
Product Development Activities
(The list continues)
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I)
Comparative Analysis
Pre-clinical & Discovery Stage Products
Comparative Analysis
Therapeutic Assessment: Active Products
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Inactive Products
Comparative Analysis
Appendix
LIST OF TABLES
Table 1: Total Products for Retinal Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products
Table 1: Total Products for Retinal Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products
LIST OF FIGURES
Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Fundus photographs of healthy and RP affected eyes
Figure 3: Color photo and auto fluorescent fundus image of Stargardt disease
Figure 4: Total Products for Retinal Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Product Type
Figure 10: Assessment by Stage and Product Type
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Inactive Products
Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Fundus photographs of healthy and RP affected eyes
Figure 3: Color photo and auto fluorescent fundus image of Stargardt disease
Figure 4: Total Products for Retinal Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Product Type
Figure 10: Assessment by Stage and Product Type
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Inactive Products
